Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Grifols, S.A. is one of the best healthcare stocks on this list.

TheFly reported on April 2 that CBC News reported that Health Canada introduced new regulatory conditions on GRFS’ paid plasma collection centers nationwide after repeated inspection failures revealed ongoing operational issues. These included gaps in donor screening, inadequate staff training, and non-compliance with standard procedures. The measures will remain until the company demonstrates consistent adherence to regulatory requirements.

Separately, on April 13, Grifols, S.A. (NASDAQ:GRFS) announced plans to repurchase €500 million of its 7.5% senior secured notes maturing in 2030 as part of efforts to lower borrowing costs and reinforce its financial position. The move targets the reduction of its most expensive debt and aligns with broader refinancing initiatives. The company recently completed a strong loan syndication, including an expanded Term Loan B of about €3 billion and a $2 billion revolving credit facility, supported by institutional investors.

Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers

Following the expected completion of this refinancing, GRFS will not face significant debt maturities until late 2028. These actions are designed to decrease overall debt levels, reduce interest expenses, and improve the company’s debt timeline while preserving liquidity. The planned note redemption is contingent upon the closing of the new financing arrangements and the successful restructuring of debt obligations due in 2027.

Grifols, S.A. (NASDAQ:GRFS) is a global healthcare company specializing in plasma-derived therapies and transfusion medicine. It develops and manufactures biologics to treat chronic and rare diseases, operating an extensive plasma collection network and advanced production facilities worldwide.

While we acknowledge the risk and potential of GRFS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GRFS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.